Condition
Adult Anaplastic Meningioma
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (2)
Trial Status
Completed2
Withdrawn1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01125046Phase 2Completed
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
NCT01234805Not ApplicableTerminated
Yoga Therapy in Treating Patients With Malignant Brain Tumors
NCT02194452Not ApplicableWithdrawn
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
NCT00492089Phase 2Completed
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Showing all 4 trials